Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 1043Lung Neoplasms 800Small Cell Lung Carcinoma 193Breast Neoplasms 158Colorectal Neoplasms 156Neoplasms 128Melanoma 116Ovarian Neoplasms 111Pancreatic Neoplasms 106Stomach Neoplasms 95Neoplasm Metastasis 88Esophageal Neoplasms 77Squamous Cell Carcinoma of Head and Neck 75Prostatic Neoplasms 66Uterine Cervical Neoplasms 65Head and Neck Neoplasms 65Endometrial Neoplasms 61Triple Negative Breast Neoplasms 59Carcinoma, Renal Cell 58Colonic Neoplasms 57Mesothelioma, Malignant 48Adenocarcinoma of Lung 48Urinary Bladder Neoplasms 47Carcinoma, Hepatocellular 46Mesothelioma 42Sarcoma 40Brain Neoplasms 40Liver Neoplasms 38Disease 34NSCLC 33

Interventions

aumolertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor × Thoracic × Clear all
NCT04216121 2024-07-01

LAT-FLOSI

Universitaire Ziekenhuizen KU Leuven

Recruiting
39 enrolled
Thoracic

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

NCT06102928 2023-10-26

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Kunming Medical University

Phase NA Recruiting
30 enrolled
Thoracic

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡